Cardinal Health, Inc. (NYSE: CAH) is a Healthcare company (Medical - Distribution) with a market capitalization of $65.6B. The Maz Rating grades it against the other companies in its sector.
Cardinal Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $283.85, Cardinal Health, Inc. trades at 36.6x trailing earnings and 0.3x sales, with an EV/EBITDA of 19.3. Over the last twelve months it generated about $257.8B of revenue and $1.8B of net income. It runs a gross margin of 3.9%, an operating margin of 1.0% and a net margin of 0.7%. It shows return on equity of -62.6%, return on invested capital of 14.3% and a free cash flow yield of 7.5%. On the balance sheet: a debt-to-equity ratio of -2.91 and a current ratio of 0.88. Over the past 52 weeks the share price ranged from $180.45 to $286.29, with a beta of 0.52.
Cardinal Health, Inc. pays a dividend yielding 0.72%, with 27% of earnings paid out. Its Maz Dividend Score is 4.23 out of 5, ranked against the other dividend payers in its sector (Safety 3.77, Growth 2.97, Yield 3.03, Consistency 3.88).
33 Wall Street analyst ratings cover the stock: 19 Buy and 14 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Cardinal Health, Inc. (CAH) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 15.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.20% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 15.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.20% / 33% · Receivables / Mkt Cap (36m) 25.4% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 15.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.20% / 33.33% · Receivables / Mkt Cap (24m) 25.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 15.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.27% / 33.33% · Receivables / Avg Assets (4Q) 24.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 14.8% / 33.33% · (Cash+ST Inv) / Total Assets 8.84% / 33.33% · (Cash+Recv) / Total Assets 33.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Cardinal Health, Inc. (CAH) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
Yes. Cardinal Health, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Cardinal Health, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.